secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2026-07-02T20:05:35+00:00
Accession:  0001104659-26-080311
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode adjourns annual meeting to July 20 pending Nasdaq approval of stock conversion
--------------------------------------------------------------------------------

- Annual meeting adjourned from July 2 to July 20, 2026, at 9:30 a.m. ET.
- All proposals have received necessary stockholder support, but Nasdaq has not yet approved initial listing application for conversion of Series A and B preferred stock to common.
- Company believes it meets Nasdaq Capital Market initial listing criteria, but no assurance of outcome or timing.
- Record date remains May 28, 2026; stockholders who haven't voted can vote via proxy or at reconvened meeting.
- No changes to proposals; company continues soliciting votes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465926080311/0001104659-26-080311-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465926080311/tm2619681d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-080311

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer